Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis

BACKGROUND: Pancreatic cancer ranks as the fourth leading cause of cancer-related mortality in the USA. And gemcitabine has been the standard of care for advanced pancreatic cancer. However, a combined use of gemcitabine plus cisplatin (GemCis) has shown promising efficacies in pancreatic cancer pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Surg Oncol
Autors principals: Ouyang, Guoqing, Liu, Zhipeng, Huang, Shengfu, Li, Qianglong, Xiong, Li, Miao, Xiongying, Wen, Yu
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4772457/
https://ncbi.nlm.nih.gov/pubmed/26927942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12957-016-0813-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars